Accueil   Diary - News   All events I4ID2019




The 3nd Immunotherapies & Innovations for Infectious Diseases Congress 2019 (I4ID2019), organized by BIOASTER, MabDesign and Lyonbiopole, is to foster interactions between pharmaceutical industries, research labs, service providers, technology developers, and clinicians and therefore contribute to the development of innovative therapies against infectious diseases with multidisciplinary approaches.


The program of I4ID2019 will include 3 tracks with keynote lectures, parallel plenary sessions, pitch talks and industrial talks covering the latest developments and highest innovative projects in the field. Furthermore, it will be possible to set up, through an online platform, business meetings during both days (partnering)


The topics covered during this congress are:

  • Track 1 - Innovative therapeutic approaches to fight infectious diseases
    • Immunotherapy (mAbs, exosomes, vaccines)
    • Phagotherapy
    • Microbiota
    • Antimicrobials


  • Track 2 – Detection, Diagnosis & Biomarkers – Fast, efficient and robust new strategies
    • New diagnosis tools
    • AI & Big data for diagnosis
    • Identification of new biomarkers
    • New rapid AST in infectious diseases


  • Track 3 – Monitoring, Epidemiology & Control – Management & follow-up of infectious diseases
    • Epidemiology
    • New NGS strategies
    • Real-time follow up
    • AI & Big Data in epidemiology






More information and registration 

See all events

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to More details are available by clicking here I agree